{E5132227.DOC;1}
FORM 6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month ended
Commission File
Number
December 2005 1-32608
VIREXX MEDICAL CORP.
(Translation of registrant's name
into English)
8223 Roper Road NW, Edmonton,
Alberta, Canada T6E 6S4
(Address of principal executive
offices)
Indicate by check mark whether the registrant files or will file
annual reports under cover Form 20-F or Form 40-F.
Form 20-F ? Form 40-F ?
Indicate by check mark if the registrant is submitting the Form 6-
K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-
K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
Indicate by check mark whether by furnishing the information
contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule 12g3-2(b)
under the Securities Exchange Act of 1934.
Yes ..... No ..X..
If "Yes" is marked, indicate below the file number assigned to
the registrant in connection with Rule 12g3-2(b): 82- ________
EXHIBIT LIST
Exhibit Description
99.1 News (ViRexx Acknowledges Contribution of Former
Release Executive)
99.2 News (ViRexx Announces Listing on AMEX)
Release
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
VIREXX MEDICAL CORP.
Date: January 12, 2006 By: /s/ Marc Canton
Marc Canton, President